Product Images Myrbetriq

Myrbetriq is a medication used for urinary incontinence. The NDC number is 70518-3158-01 and it contains Mirabegron which is an extended-release tablet. The tablets come in 25mg and are manufactured by Astellas Pharma US, Inc. in Northbrook, IL. It is important to keep the medication out of the reach of children and to swallow the tablet whole, without cutting or crushing it. The medicine must be stored at a temperature between 20-26°C (63-77°F) with excursions permitted to 15-30°C (59-86°F). There is a warning against cutting or crushing the tablet and the package insert should be consulted for directions for use. The text is readable.*

Myrbetriq is a medication with NDC number 70518-3158-03, with an extended-release source NDC of 00469-2601-30. It is manufactured by Astellas Pharma US, Inc. in Northbrook, IL 60082, with a strength of 25 mg. The medication should be kept out of reach of children, and the tablet must be swallowed whole and should not be cut, crushed, or chewed. The directions for use can be found in the package insert. The medication should be stored between 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) [See USP]. The remaining text is not available.*

Myrbetriq is a tablet medication manufactured by Astellas Pharma US, Inc located in Northbrook, IL 60082. The National Drug Code (NDC) for this medication is 70518-3158-00 and the Extended-Release Source NDC is 00469-2601-90. The medication contains 25mg of Mirabegron LoT# and cannot be cut or crushed. The directions for use can be found on the package insert. The medication should be stored between 20-26°C (63-77°F) and kept out of reach of children. The text also contains a warning about swallowing the tablet whole, and a reference to RXONLY.*

This appears to be a table containing information on the effect of CYP3A/Pgp inhibitors/inducers on drug pharmacokinetics. The table shows the PK fold change and 90% confidence interval for different drugs (Ketoconazole, Rifampicin, Solifenacin, Tamsulosin, and Metformin) and their recommended dose adjustments. However, the table seems to be missing some information and context, and it is unclear what the drugs are used for.*

This text provides information about the recommended dose adjustments for certain drugs that are substrates of the enzymes CYP3A4 and CYP2D6. The table shows the fold change and 90% confidence interval (CI) for PK, as well as recommendations for adjusting the dose based on Cmax and AUC values. Specifically, solifenacin, ethinylestradiol, and levonorgestrel do not require dose adjustment, whereas caution is advised for desipramine and metoprolol. Tamsulosin does not require dose adjustment, while digoxin requires a starting dose adjustment. Recommendations for (R) and (S) warfarin are provided in a footnote, and metformin does not require dose adjustment.*

This appears to be a chart of numerical values for a study evaluating the mean change from baseline for a placebo and a mirabegron 50 mg treatment over the course of 12 weeks. There is also a label indicating "N o o ol" but it is unclear what this refers to without additional information.*

This text appears to be a small section of a chart or table displaying numerical data related to a clinical trial for the medication mirabegron. The numbers in the first column could represent different measurements or time points, while the values in the remaining columns may be changes or results attributed to the medication. Without additional context, it is difficult to provide a specific description of what the data represents.*

This appears to be a chart or graph with numerical values and labels indicating different time intervals and treatment groups. It is unclear what the variables represent or what the units are, so it is not possible to provide a more specific description.*

This is a table showing the adjusted change from baseline in percentages at weeks 4, 8, and 12 for different doses of a drug (M25mg and M50mg) compared to a placebo. The abbreviation EoT stands for End of Treatment and LOCF stands for Last Observation Carried Forward.*